Psychiatry
B orderline personality disorder (BPD), the focus of this issue of Australasian Psychiatry, has had a chequered history in psychiatry. In 1938 Stern used the term 'borderline' to identify a group of patients he regarded as psychologically functioning between neurosis and psychosis. This group did not do well with psychoanalytic treatment approaches, which led to the therapeutic nihilism that surrounded BPD over many years. Not until Linehan in 1991 and Stevenson and Meares in 1992 1 published findings on successful psychotherapy for BPD did things begin to change. Several other treatments were then developed for BPD and empirically validated as effective, including dialectical behavioural treatment, mentalization-based treatment, schema-based psychotherapy and transference-focused psychotherapy. 2 Important research followed, showing that psychological treatments which employed the factors common to those specific treatments were equally effective overall. 3 This boded well for people with BPD. These treatments do not require extensive training for clinicians. They do need to be applied within a structured format, offer psychoeducation about the disorder and clarity about the treatment planned, together with consistent application of the common factors. Such a structured approach offers a 'containing' function wherein the patients can learn to link behaviour with feelings, regulate emotions and impulses and develop an ability to reflect on minds (mentalize), thus improving their quality of life.
Another positive finding from research is that the prognosis of BPD, formerly regarded as poor, has been shown in a more positive light by two long-term prospective studies. Zanarini's group at McLean has now conducted more than 20 years of prospective research on the outcome in 290 patients with severe BPD at two-yearly intervals. 4 They reported 35% remission at 2 years, 50% at 4 years, 88% at 8 years, moving through to 99% achieving at least a 2-year remission at 16 years, with remission defined as no longer meeting the criteria for BPD. The figures for recovery from BPD (defined as no longer meeting BPD criteria and having at least one close relationship and the capacity for full-time work or study) were also impressive and recurrence was unusual. The Collaborative Longitudinal Personality Disorders Study (CLPS) 5 found 10% remission at 6 months, 25% in 1 year, 45% at 2 years and 85% at 10 years with 15% relapse rate during follow-up. Significantly, the first symptoms to remit were those that cause most anxiety to clinicians, namely impulsive behaviours including suicidal and self-harming acts. But there is a rub. Both studies revealed that patients who had remitted from BPD often continued to have psychosocial difficulties with relationships and employment. Much more work is needed to assist people with BPD to function in relationships and to gain and maintain employment, not simply to achieve remission from the disorder.
Despite the positive findings, a major problem exists in Australia. Many people with BPD are unable to access appropriate treatment. Psychological approaches including individual and group psychotherapies are recognized as the first-line treatment for the disorder, 6 while medication has only an adjunctive role for short-term relief of troubling symptoms. Yet in the public psychiatric system, at least in Victoria, psychological and psychotherapeutic treatments have been squeezed out by increased pressures affecting that system for many years. This has led to a focus on brief treatments, crisis intervention and rapid patient turnover at the expense of psychological treatments which are regarded as too time consuming. Patients with BPD have thus been robbed of essential treatment. A generation of psychiatrists in training has also been left poorly equipped to treat these patients. Let us get on and fix this problem now.
The BPD field now recognizes that short-term treatments can be effective, especially for mild cases or the recently Making psychological treatments for borderline personality disorder available diagnosed, whose difficulties have not yet become entrenched. These treatments must be made available. Longer term more intensive treatment will always be required for the most severely ill group. But a welldesigned (and I mean well-designed) 'stepped care' approach to BPD enables effective treatment of many more patients. This stepped-care approach, combined with training in 'common factors' treatment for clinicians in the public sector, is the way forward.
Several well-designed brief intervention models are available. 7, 8 They educate participants about BPD and offer skills information and training, usually over 10 sessions. Patients for whom brief interventions are not suitable (ongoing suicidality, severe self-harming behaviours for example) are identified during assessment and assigned to more appropriate treatment. Moderate cases will benefit from psychotherapy using the 'common factors' approach, probably not long term, but often requiring further help at times of crisis.
BPD is a serious mental illness that causes great suffering to patients, and to their families, friends and carers. As Gunderson wrote in 2009 9 : 'In modern psychiatry borderline personality disorder has become the major container for sustaining the relevance of mind'. It remains so. It is not possible to adequately treat BPD without deep reflection on the mind of the patient. It is rewarding work, not least for the opportunity to improve someone's life and relieve intolerable suffering.
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The search for biomarkers of pathological processes has had growing prominence in psychiatry over the last few decades, particularly for nosological initiatives such as the fifth edition of the Diagnostic and Statistical Manual and the Research Domain Criteria. However, similar to developments in psychiatric genetics, the main effect of psychiatric biomarker research has been rapid escalation in the complexity of models used to understand the results, with limited impact on clinical outcomes to date.
In this interview conducted at the RANZCP's 2019 Congress in Cairns, Professor Chris Stapelberg, Joint Chair in Mental Health for Bond University and the Gold Coast University Hospital, describes his approach to biomarker research and how an understanding of the complex interrelationships between psychological, immune and neuroendocrine systems may lead to individually targeted treatment regimes known as precision psychiatry.
Cover art
The cover art by NEG comes from the Cunningham Dax Collection. The artwork has been chosen to reflect the articles on borderline personality that are featured in this issue. The artist says this about her artwork:
Since the age of nine, NEG has had an experience of mental health issues. NEG took part in Prahran Mission's Second Story program, as well as taking a place as an artist in Stables Studio. She has undertaken a Writing and Editing course at RMIT, as well as various art therapy sessions. NEG has also undertaken classes in Oriental Ink Brush, 'Which I love because I can paint tranquility and in the doing feel some tranquility myself'. She says that, '[I feel] that people don't know what it's like to live with borderline personality disorder and I think my work/writing shows something of that. I hope that people can learn from it'.
